This evolution has yielded more definitive treatment outcomes for patients with diverse genetic and molecular profiles.[4] Among the therapeutic advancements, anti-angiogenic drugs have become integral in NSCLC management due to their versatility in combination with various agents and their favorable safety profile.[5,6] Notably, Endostar, a chemically modified recombinant human endostatin developed independently in China, has demonstrated superior stability and safety in treating a spectrum of solid tumors, including NSCLC, cervical cancer, and nasopharyngeal carcinoma.[7–9]. This evidence concerns the gene COL18A1 and non-small cell lung carcinoma.